Abstract 891P
Background
HNSCC is a heterogeneous group with diverse incidence and survivals worldwide. Factors such as ethnicity, lifestyle, and healthcare systems contribute to these differences. This study aimed to describe the landscape of HNSCC patient characteristics, treatments, and survival outcomes in Thailand over 13 years.
Methods
We retrospectively analyzed data from a multicenter database of patients with HNSCC treated between 2008 and 2020 in Thailand.
Results
A total of 6,319 patients from 4 large cancer centers were analyzed. Most patients had nasopharynx (NP 33%), oral cavity (OC 23%), oropharynx (OR 17%), larynx (LA 15%), or hypopharynx (HP 8%) as primary sites. The incidence of HPV-related oropharyngeal squamous cell carcinoma had been rising from 13% in 2008 to 42% in 2019-2020. Most patients presented with locally advanced (LA) stage (stage IVa/b 50%, and III 26%), and the proportion of LA stages increased annually. Chemoradiotherapy (CRT) (43%) and surgery (31%) with or without adjuvant (chemo)radiotherapy were the most common definitive treatments. Cisplatin (79%) was most used with CRT, followed by carboplatin (20%) and cetuximab (1%). Local, regional, and distant recurrences were observed in 46%, 19%, and 35% of all patients, respectively. Overall survival (OS) improved annually across all subsites. The use of intensity-modulated radiotherapy (IMRT) increased from 25% in 2008 to 90% in 2019-2020. Patients treated with IMRT had significantly longer OS compared to non-IMRT (HR 0.52, 95% CI 0.46-0.58; p<0.001). Table: 891P
3-yr OS | 5-yr OS | 10-yr OS | |
Year of diagnosis 2008 2009-10 2011-12 2013-14 2015-16 2017-18 2019-20 | 43% 62% 74% 71% 70% 73% 78% | ||
Primary site NP OP OC LA HP | 69% 51% 58% 71% 47% | 60% 45% 54% 64% 42% | 48% 38% 44% 53% 35% |
Radiotherapy technique 2D 3D IMRT | 58% 63% 79% | 49% 54% 71% | 34% 44% 59% |
Conclusions
This is the largest study of HNSCC patients in Thailand, highlighting the increasing survival outcomes despite the presentation of locally advanced stages. The growing utilization of IMRT might contribute to the improvement of survival outcomes for HNSCC patients in Thailand.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was funded by the National Research Council of Thailand (NRCT) (Government Research Grant through Mahidol University #3484 (Project #6908)), and the Health Systems Research Institute (HSRI) (grant number 63-140), and the NSRF via the Program Management Unit for Human Resources & Institutional Development, Research and Innovation (grant number B05F650041).
Disclosure
N. Ngamphaiboon: Financial Interests, Personal, Invited Speaker: Roche, MSD, Merck, Eisai; Financial Interests, Personal, Advisory Board: MSD, BeiGene, BMS, Roche, Merck; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Local PI: MSD, Roche, RAPT therapeutics, BeiGene, Boehringer Ingelheim Pharmaceuticals; Non-Financial Interests, Other, Safety Monitoring Committee (SMC): Boehringer Ingelheim Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
910P - Machine learning-based survival prediction model for postoperative parotid mucoepidermoid carcinoma
Presenter: Chen Zihan
Session: Poster session 12
911P - Post-radiotherapy (RT) Epstein-Barr virus (EBV) DNA dynamics identifies optimal timepoint for stratification of high-risk nasopharyngeal carcinoma (NPC)
Presenter: Janice Ser Huey Tan
Session: Poster session 12
912P - Toripalimab in combination with anlotinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: The interim analysis of the single-arm, phase II TORAL study
Presenter: QingQing Cai
Session: Poster session 12
916P - Reducing radiation-induced temporal lobe injury by changing tumor prescription dose in nasopharyngeal carcinoma
Presenter: Xiao Xiao
Session: Poster session 12
917P - Radiation-induced nasopharyngeal necrosis in locally-recurrent nasopharyngeal carcinoma patients after re-radiotherapy
Presenter: Runda Huang
Session: Poster session 12
918P - SPP1-related M2 macrophage signatures predict prognosis and immunotherapy response in patients with nasopharyngeal carcinoma
Presenter: Li Ying
Session: Poster session 12
919P - A prognostic model of nasopharyngeal carcinoma based on 18F-FDG PET-CT radiomic parameters and clinical characteristics of patients
Presenter: Wu xi
Session: Poster session 12
920P - Envafolimab plus chemoradiotherapy for locally advanced nasopharyngeal carcinoma (NPC), a prospective, single-armed phase II trial
Presenter: Xiaohui Wang
Session: Poster session 12
921P - HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer
Presenter: Lisle Nabell
Session: Poster session 12